What is the 13F Pro Quality Score for AIRS?

13F Pro ranks Airsculpt Technologies, Inc. (AIRS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AIRS's current score at https://13fpro.ai/research/AIRS (free sign-up required for the full ranking).

Where does 13F Pro source AIRS data?

All Airsculpt Technologies, Inc. fundamentals and ownership data come directly from SEC EDGAR. Airsculpt Technologies, Inc. files with the SEC under CIK 1870940. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AIRS in?

Airsculpt Technologies, Inc. (AIRS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AIRS research updated on 13F Pro?

AIRS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Airsculpt Technologies, Inc.(AIRS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1870940 AIRS stock profile & AI dashboard →

13F Pro Quality Score

24.3/100

Rank #2,587 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

12.1/100

Profitability

19.1/100

Balance Sheet

19.5/100

Earnings Quality

30.0/100

Free Cash Flow

52.0/100

Institutional Flow

4.1/100

Revenue Scale

21.7/100

Dilution Risk

46.5/100

AIRS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Airsculpt Technologies, Inc. (AIRS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AIRS at 24.3/100 on a 32-signal composite quality model, placing it at rank #2,587 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (4.1) and revenue growth (12.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Airsculpt Technologies, Inc. reports quarterly revenue of $39.4M, net income of $-2.4M, an operating margin of -4.6%. Top institutional holders of AIRS by reported 13-F value include Vesey Street Capital Partners, L.L.C., BALYASNY ASSET MANAGEMENT L.P., FourWorld Capital Management, based on the most recent SEC filings. AIRS trades on the Nasdaq exchange and files with the SEC under CIK 1870940. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Airsculpt Technologies, Inc. directly from SEC EDGAR. Airsculpt Technologies, Inc.'s 13F Pro composite quality score has ranged between 8 and 56 since 2022, currently 24.3 — a declining long-term trajectory across 51 quarterly and live scoring snapshots.

✦

Fun facts about Airsculpt Technologies, Inc.

Quirks, history, and lore behind AIRS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Florida · operates in the elective medical procedures space.
2
The Numbers
A small-cap company with annual revenue in the range of roughly $200 million, operating a growing network of outpatient surgical centers across the U.S.
3
The History
Founded in the 2010s, the company commercialized a proprietary minimally invasive body contouring technique and went public on Nasdaq in 2021.
4
The Secret
Unlike traditional liposuction performed in hospitals, its procedure is done under local anesthesia only — patients are awake the whole time and walk out the same day.
5
The Lore
The company's proprietary technology uses powered cannulas to remove fat more precisely than conventional methods, and it fiercely guards its patented surgical approach as its core moat.
6
The Giveaway
Its very name tells you what it does: sculpting bodies with air-powered tools — this cosmetic fat-removal company's ticker even spells out its breezy ambitions.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$39.4M

Net Income

Q1 2026

$-2.4M

Free Cash Flow

Q1 2026

$5.2M

Operating Margin

Q1 2026

-4.6%

D/E Ratio

Q1 2026

0.50

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.9% YoY

$151.8MFY 2025

FY19 $41.2MFY20 $62.8MFY21 $133.3MFY25 $151.8M

Net Income

-210.6% YoY

$-11.7MFY 2025

FY19 $-2.2MFY20 $7.6MFY21 $10.6MFY25 $-11.7M

Operating Income

-173.3% YoY

$-11.6MFY 2025

FY19 $663.0KFY20 $10.0MFY21 $15.8MFY25 $-11.6M

EPS (Diluted)

-1800.0% YoY

$-0.19FY 2025

FY19 —FY20 —FY21 $-0.01FY25 $-0.19

Total Assets

-6.6% YoY

$187.3MFY 2025

FY19 —FY20 $179.6MFY21 $200.6MFY25 $187.3M

Total Debt

-26.3% YoY

$61.5MFY 2025

FY19 —FY20 $32.9MFY21 $83.5MFY25 $61.5M

Op. Cash Flow

-88.4% YoY

$3.1MFY 2025

FY19 $4.9MFY20 $14.0MFY21 $26.6MFY25 $3.1M

Metric	FY 2025	FY 2021	FY 2020	FY 2019
Revenue	$151.8M +13.9%	$133.3M +112.4%	$62.8M +52.2%	$41.2M
Net Income	$-11.7M -210.6%	$10.6M +39.3%	$7.6M +442.5%	$-2.2M
Operating Income	$-11.6M -173.3%	$15.8M +57.2%	$10.0M +1413.3%	$663.0K
EPS (Diluted)	$-0.19 -1800.0%	$-0.01	—	—
Total Assets	$187.3M -6.6%	$200.6M +11.7%	$179.6M	—
Total Debt	$61.5M -26.3%	$83.5M +153.5%	$32.9M	—
Operating Cash Flow	$3.1M -88.4%	$26.6M +90.8%	$14.0M +182.6%	$4.9M

AI Insight: AIRS Ratio Trends

AIRS remains structurally unprofitable despite a slight TTM D/E improvement to 0.50, with extreme quarterly earnings volatility masking any durable margin recovery.

• Operating margin swung violently: from -27.9% in Q3 2025 to -3.0% in Q4 2025, then -4.6% in Q1 2026 — no stable recovery evident.

• Leverage has improved: D/E fell from a peak of 0.95 in Q4 2024 to 0.50 in the TTM period ending Q1 2026.

• ROIC turned briefly positive at 2.1% in Q2 2025 but reverted to -4.8% in Q1 2026, signaling no sustained capital efficiency.

• TTM net profit margin stands at -7.4%, with ROE at -11.2% and ROA at -5.8% — all negative across core profitability metrics.

⚠ Q3 2025 operating margin collapsed to -27.9% — likely a one-off charge; confirm whether it recurs or distorts trend reads.

⚠ Q4 2025 showed rare positive NPM of 3.8% and ROE of 5.9% — monitor whether Q1 2026 reversion is seasonal or structural.

⚠ D/E declining to 0.50 is encouraging, but negative ROIC means debt costs exceed returns — debt reduction pace is critical.

Get alerted when AIRS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Airsculpt Technologies, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AIRS

Vesey Street Capital Partners, L.L.C.
$85.8M30,324,180 sh
BALYASNY ASSET MANAGEMENT L.P.
$6.6M2,326,690 sh
FourWorld Capital Management LLC
$2.8M987,757 sh
BlackRock, Inc.
$2.3M804,079 sh
WEXFORD CAPITAL LP
$1.9M670,517 sh
UBS Group AG
$1.8M622,292 sh
BALYASNY ASSET MANAGEMENT L.P.
$1.7M614,600 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.3M474,445 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.0M368,456 sh
Saba Capital Management, L.P.
$885.9K313,043 sh

Fund	Value	Shares
Vesey Street Capital Partners, L.L.C.	$85.8M	30,324,180
BALYASNY ASSET MANAGEMENT L.P.	$6.6M	2,326,690
FourWorld Capital Management LLC	$2.8M	987,757
BlackRock, Inc.	$2.3M	804,079
WEXFORD CAPITAL LP	$1.9M	670,517
UBS Group AG	$1.8M	622,292
BALYASNY ASSET MANAGEMENT L.P.	$1.7M	614,600
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.3M	474,445
GEODE CAPITAL MANAGEMENT, LLC	$1.0M	368,456
Saba Capital Management, L.P.	$885.9K	313,043

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AIRS on your watchlist

Track score changes the day Airsculpt Technologies, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AIRS a good stock to buy?

13F Pro's AI-powered analysis of Airsculpt Technologies, Inc. (AIRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIRS are available on the AIRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AIRS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Airsculpt Technologies, Inc.'s investment landscape.